Robert C. Stein
University of London · 221 works · 9,100 citations · h-index 50
Top works
- A human phosphatidylinositol 3‐kinase complex related to the yeast Vps34p‐Vps15p protein sorting system.
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- p110δ, a novel phosphoinositide 3-kinase in leukocytes
- Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties
- Structural and functional diversity of phosphoinositide 3-kinases
- Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1
- Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
- A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer
- Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin
- Topical calcipotriol treatment in advanced breast cancer
- PI3-kinase inhibition: a target for drug development?
- Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
- POTENCY AND SELECTIVITY OF THE NON‐STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS
- The study of phosphoinositide 3-kinase function.
- Three-dimensional in vitro tissue culture models of breast cancer — a review
- The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
- Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.
- Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer